Eslicarbazepine acetate (ESL) is a new molecular entity belonging to the dibenzazepine carboxamide chemical class of antiepileptic drugs. ESL, carbamazepine (CBZ), and oxcarbazepine (OXC) all contain a dibenzazepine nucleus bearing a 5-carboxamide substitute, but ESL is structurally different at the 10,11 position.[@b1],[@b2] This molecular variation results in differences in metabolism and pharmacology. Following oral administration, ESL is rapidly and extensively converted to the major active metabolite, (S)-licarbazepine (eslicarbazepine) via hydrolytic first-pass metabolism;[@b2],[@b3] consequently, ESL is undetectable in plasma as early as 15 min postdose.[@b4] Approximately 95% of oral ESL exposure is accounted for by eslicarbazepine, and \<1% by OXC.[@b5] In contrast, the major metabolite of OXC is the monohydroxy derivative (MHD: a racemic mixture of 4:1 eslicarbazepine to (R)-licarbazepine);[@b6] 3% of OXC exposure is accounted for by residual oxcarbazepine.[@b5] In contrast to CBZ, ESL is not metabolized to potentially toxic epoxide metabolites,[@b3] and is not susceptible to metabolic autoinduction.[@b7],[@b8]

Eslicarbazepine is believed to act by stabilizing the inactivated state of voltage-gated sodium channels (VGSCs), and shows higher selectivity for the inactivated state of the channel versus the resting state[@b3] (Ki\[resting\]/Ki\[inactivated\] = 60) than CBZ (Ki\[r\]/Ki\[i\] = 19), OXC (Ki\[r\]/Ki\[i\] = 44), and the enantiomer (R)-licarbazepine (Ki\[r\]/Ki\[i\] = 28).[@b9] The greater selectivity of eslicarbazepine for the inactivated state of VGSCs is thought to confer a greater inhibitory effect on rapidly firing (or "epileptic") neurons compared with neurons in the resting state.[@b10]

Previous double-blind placebo-controlled studies demonstrated that ESL (800 or 1,200 mg once-daily \[QD\]) is well-tolerated as adjunctive therapy and is significantly more effective than placebo in patients with partial-onset seizures refractory to treatment with between one and three concomitant antiepileptic drugs (AEDs).[@b11],[@b12] In these studies, ESL significantly reduced standardized seizure frequency (per 4 weeks) during a maintenance period of 12 weeks, and increased the rate of response (defined as the proportion of patients with ≥50% reduction in seizure frequency) compared with placebo.

This article reports primary efficacy and safety data from an additional double-blind placebo-controlled trial (the trial is registered at ClinicalTrials.gov, number NCT00988429) that was undertaken to evaluate further the efficacy, safety, and tolerability of ESL as adjunctive therapy in patients aged ≥16 with refractory partial-onset (focal) seizures receiving one or two AEDs. The impact of an alternative seizure diary format on evaluation of ESL efficacy was also assessed. Previous trials of ESL made use of event-entry (EE) diaries (in which patients provide entries only when seizures occur); however, when using EE diaries, it is not possible to determine whether days with no entry reflect a true absence of seizures, or failure of the patient to make a diary entry. To address this issue, the current trial mainly used daily entry (DE) diaries, in which patients were instructed to document seizure data every day, irrespective of whether a seizure had occurred. To our knowledge, this is the first clinical trial to report efficacy data of an AED in patients with partial-onset seizures using either EE or DE diaries.

Methods
=======

Study design
------------

This randomized, placebo-controlled, double-blind, parallel-group study was conducted at 173 centers in 19 countries (Argentina, Australia, Brazil, Belgium, Canada, Cyprus, France, Germany, Greece, Hungary, India, Italy, Poland, Turkey, South Korea, Romania, South Africa, Ukraine, and the United States) between December 2008 and January 2012.

Patients aged ≥16 years were eligible for screening if they satisfied all of the following criteria: in general good health except for a documented diagnosis of epilepsy for a minimum of 12 months; had ≥4 simple or complex partial-onset seizures (with or without secondary generalization) within the 4-week period prior to screening; treated with a stable dose of one to two AEDs (except OXC) for ≥1 month prior to screening (vagus nerve stimulation therapy was not considered to be an AED and was permitted, as was vigabatrin, if the patients were stable and safety was monitored). Eligibility criteria for randomization included the following: ≥8 partial-onset seizures that were documented in a diary during the baseline period (with ≥3 seizures during each 4-week period and no seizure-free interval exceeding 28 consecutive days) and satisfactorily completed diaries.

Criteria for exclusion included the following: simple partial seizures with no motor symptoms; primarily generalized seizures; known progressive neurologic disorder; status epilepticus or cluster seizures within 3 months before screening, or seizures of nonepileptic or psychogenic origin within 2 years; history of schizophrenia or suicide attempts; current treatment with OXC (Patients taking OXC were excluded from study participation to avoid the possibility of excessive exposure to eslicarbazepine.), or using benzodiazepines \>2 times per week (except when used chronically as an AED); hypersensitivity to CBZ or CBZ derivatives; second- or third-degree atrioventricular blockade not corrected with a pacemaker; relevant clinical laboratory abnormalities; a positive major histocompatibility complex, class I, B\*1502 test (for patients of Asian ancestry); at randomization, inadequate compliance to the study protocol during the baseline period.

Following screening, patients entered an observational 8-week baseline period, during which they were instructed on how to complete their seizure diaries. Patients with at least eight seizures during the baseline period then entered a double-blind phase that comprised a 2-week titration period, a 12-week maintenance period, and a 2-week tapering-off period. At the start of the titration period, eligible patients were randomized in a 1:1:1 ratio to receive placebo, ESL 800 mg, or ESL 1,200 mg (all QD). Randomization and allocation to treatment group was performed using an interactive voice-response system. The randomization code was prepared by a third party using a computer-generated schedule, and followed a permuted-block design (block size = 8). Each patient was assigned a unique screening number that was used for identification purposes throughout the study. Investigators were provided with a sealed envelope for each patient containing the patient\'s unique randomization number but were blinded to study treatment. Treatment codes remained blinded throughout the study. During the titration period, patients in the ESL 800 mg group started treatment at 400 mg QD, and those in the ESL 1,200 mg group started at 800 mg QD (in each group, the dose was increased by 400 mg at the end of the first week). Patients who completed the maintenance phase could enter a 1-year open-label extension study.

When the study was first initiated, EE diaries were used to record seizures; patients (with or without assistance) recorded each seizure by date, type, and time of occurrence during the baseline and double-blind treatment phases. Following a protocol amendment, EE diaries were replaced with DE diaries. Patients who were already enrolled prior to the protocol amendment continued to use EE diaries for the duration of the study. Both types of diary were provided in printed form. Of the intent-to-treat (ITT) population, approximately 29% and 71% of patients used EE and DE diaries, respectively. EE and DE subgroups were well matched in terms of demographics and baseline clinical characteristics, although the proportion of patients using vagus nerve stimulation at baseline (8% vs. 0.3%) and the proportion of Asian patients (27% vs. 1.6%) were greater for the DE than for the EE group.

Seizure types were classified according to the International League Against Epilepsy (ILAE) Revised Clinical and Electroencephalographic Classification of Epileptic Seizures (1981) into simple partial seizures, complex partial seizures, partial seizures evolving to secondarily generalized seizures, and unclassified.[@b13] In addition, investigators could indicate "other" if the seizure type was unknown or not otherwise captured.

Assessments
-----------

### Efficacy

The primary efficacy variable was seizure frequency, standardized per 4 weeks (standardized seizure frequency). The primary assessment of efficacy was based on the least squares (LS) mean--adjusted seizure frequency during the maintenance period. For the primary end point, all patients with diaries (of either type) were considered. Secondary efficacy variables included the following: seizure frequency during the 2-week titration period and the maintenance period combined; proportion of responders (patients with ≥50% reduction in seizure frequency vs. baseline)*;* reduction in seizure frequency from baseline; proportion of patients with exacerbations in seizure frequency ≥25% versus baseline; reduction in seizure frequency according to seizure type; proportion of seizure-free patients during the maintenance period***;*** change in Clinical Global Impression (CGI) score from baseline;[@b14] and change in Quality of Life in Epilepsy Inventory-31 (QOLIE-31) total score from baseline.[@b15] CGI scores (global improvement \[CGI-I\], severity of illness \[CGI-S\], and therapeutic effect \[CGI-efficacy\]) and QOLIE-31 ratings were evaluated at randomization and the end of the maintenance period.

### Safety and tolerability

Adverse events (AEs) were reported at each clinic visit (irrespective of whether they were considered to be related to the study drug) and coded using the Medical Dictionary for Regulatory Activities (MedDRA) version 13.1. Treatment-emergent AEs (TEAEs) were defined as AEs that occurred on or after the first dose of study drug. Other safety assessments included the following: clinical laboratory tests; vital signs; 12-lead electrocardiography measurements; and Columbia Suicide Severity Rating Scale (C-SSRS) scores.

Statistical analyses
--------------------

### Determination of sample size

For the primary efficacy analysis, the required sample size was calculated such that a treatment difference of 0.174 (standard deviation \[SD\] = 0.4) in the primary efficacy variable could be detected with 90% power (using DE diaries). Using Bonferroni adjustment for two comparisons of the two doses of active drug with placebo (α = 0.025 for each), 130 patients would be required per group to achieve 89.4% power. Assuming a drop-out rate of 10% based on previous phase III studies,[@b11],[@b12] 435 patients using DE diaries (145 patients per group) were required. Therefore, a total enrollment of 615 patients was required (435 using DE diaries and 185 using EE diaries \[the latter group was enrolled prior to the protocol amendment\]).

### Definitions

The primary efficacy analysis was based on the ITT population (all randomized patients who received at least one dose of the study drug and had at least one post-baseline seizure frequency assessment). The ITT population included patients who used either EE or DE diaries. In addition, the EE and DE diary ITT populations were analyzed separately. Supportive analyses were performed in the per-protocol (PP) population (patients in the ITT population with no major protocol deviations/violations) and the DE diary ITT population. The safety population consisted of all randomized patients who received at least one dose of study drug.

### Analysis

For the primary efficacy variable, the natural logarithm of seizure frequency was compared between groups using an analysis of covariance (ANCOVA), which models seizure frequency as a function of baseline seizure frequency and treatment (with diary type as an additional covariate). Estimates from the ANCOVA model were back-transformed using the exponential function. A two-stage gate-keeping multiple-testing procedure[@b16] was used for comparisons between ESL treatment LS means and placebo LS means for the ITT and DE diary ITT populations in the primary analysis. p-values were subject to Bonferroni adjustment in the first stage; Dunnett\'s multiple comparison procedure was used in the second stage (p-values from other analyses were not corrected for multiplicity). The proportion of responders, the proportion of patients with exacerbations in seizure frequency ≥25%, and the proportion of patients who were seizure-free were analyzed using a Cochran-Mantel-Haenszel test. The group comparisons in the reduction in seizure frequency and the change in CGI score were analyzed by ANCOVA.

This study (BIA 2-093-304) was approved by the appropriate institutional review boards, and was conducted in accordance with international and local regulations of the countries involved. Informed consent was obtained from each patient.

Results
=======

Patients
--------

The number of patients randomized and their disposition (for the safety, ITT, and PP populations) are summarized in [Figure S1](#sd1){ref-type="supplementary-material"}. The placebo and active-treatment groups were well balanced in terms of demographics and baseline characteristics (Table[1](#tbl1){ref-type="table"}).

###### 

Demographic and baseline characteristics (safety population)

  Characteristic                                                                                                                                                   Placebo (n = 224)                                 ESL 800 mg (n = 216)   ESL 1,200 mg (n = 210)
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------- ---------------------- ------------------------
  Age, years (median \[range\])                                                                                                                                    39.0 (16--67)[*a*](#tf1-2){ref-type="table-fn"}   38.5 (16--71)          38.0 (16--69)
  Male, n (%)                                                                                                                                                      112 (50.0)                                        109 (50.5)             105 (50.0)
  Ethnicity, n (%)                                                                                                                                                                                                                          
   Caucasian                                                                                                                                                       142 (63.4)                                        137 (63.4)             134 (63.8)
   Black                                                                                                                                                           8 (3.6)                                           8 (3.7)                8 (3.8)
   Asian                                                                                                                                                           46 (20.5)                                         41 (19.0)              39 (18.6)
   Other                                                                                                                                                           28 (12.5)                                         30 (13.9)              29 (13.8)
  BMI, kg/m^2^[*b*](#tf1-3){ref-type="table-fn"}                                                                                                                                                                                            
   Mean ± SD                                                                                                                                                       25.7 ± 5.8                                        26.3 ± 5.6             26.5 ± 7.0
   Median (range)                                                                                                                                                  24.8 (16.2--46.5)                                 25.7 (16.0--55.2)      25.4 (15.5--71.4)
  Duration of epilepsy (years)[*c*](#tf1-4){ref-type="table-fn"}                                                                                                                                                                            
   Mean ± SD                                                                                                                                                       21.3 ± 14.6                                       21.6 ± 13.0            21.2 ± 13.0
   Median (range)                                                                                                                                                  18.3 (1.1--63.4)                                  19.6 (1.4--53.9)       18.3 (1.1--57.3)
  Seizure frequency in the 4 weeks prior to screening[*d*](#tf1-5){ref-type="table-fn"}                                                                                                                                                     
   Mean ± SD                                                                                                                                                       18.1 ± 28.7                                       18.0 ± 35.9            17.6 ± 30.2
   Median (range)                                                                                                                                                  8 (4--282)                                        8 (1--420)             9 (4--351)
  Seizure type in the 4 weeks prior to screening,[*d*](#tf1-5){ref-type="table-fn"}^,^[*e*](#tf1-6){ref-type="table-fn"} n (%)[*f*](#tf1-7){ref-type="table-fn"}                                                                            
   Simple partial[*g*](#tf1-8){ref-type="table-fn"}                                                                                                                81 (36.8)                                         84 (39.3)              66 (32.2)
   Complex partial[*h*](#tf1-9){ref-type="table-fn"}                                                                                                               175 (79.5)                                        170 (79.4)             170 (82.9)
   Partial evolving to secondarily generalized[*i*](#tf1-10){ref-type="table-fn"}                                                                                  57 (25.9)                                         59 (27.6)              63 (30.7)
   Unclassifiable                                                                                                                                                  2 (0.9)                                           0                      3 (1.5)
   Other                                                                                                                                                           2 (0.9)                                           1 (0.5)                0
   Missing                                                                                                                                                         0                                                 1                      0
  Median (range) SSF during the baseline period[*d*](#tf1-5){ref-type="table-fn"}^,^[*j*](#tf1-11){ref-type="table-fn"}                                            9.0 (2.4--131.8)                                  8.6 (2.0--412.3)       8.9 (3.7--163.5)
  Number of AEDs used during the baseline period,[*k*](#tf1-12){ref-type="table-fn"} n (%)                                                                                                                                                  
   1                                                                                                                                                               64 (28.6)                                         60 (27.8)              59 (28.1)
   2                                                                                                                                                               158 (70.5)                                        153 (70.8)             151 (71.9)
   ≥3                                                                                                                                                              1 (0.4)                                           0                      0
  AEDs during baseline used by \>15% of patients,[*l*](#tf1-13){ref-type="table-fn"} n (%)                                                                                                                                                  
   Carbamazepine                                                                                                                                                   77 (34.4)                                         84 (38.9)              89 (42.4)
   Levetiracetam                                                                                                                                                   66 (29.5)                                         58 (26.9)              43 (20.5)
   Lamotrigine                                                                                                                                                     57 (25.4)                                         51 (23.6)              57 (27.1)
   Valproic acid                                                                                                                                                   42 (18.8)                                         46 (21.3)              41 (19.5)

AED, antiepileptic drug; BMI, body mass index; ESL, eslicarbazepine acetate; ILAE, International League Against Epilepsy; SD, standard deviation; SSF, standardized seizure frequency.

n = 223.

n = 222, 215, and 208 for placebo, ESL 800 mg, and ESL 1,200 mg, respectively.

n = 215 for ESL 800 mg.

Intention-to-treat population.

Patients may have had more than one type of seizure.

n = 220, 214, and 205 for placebo, ESL 800 mg, and ESL 1,200 mg, respectively.

Focal seizures without impairment of consciousness or awareness.

Dyscognitive seizures.

Focal seizures evolving to bilateral convulsive seizures (2010 ILAE classification).[@b17]

n = 220, 215, and 204 for placebo, ESL 800 mg, and ESL 1,200 mg, respectively.

An AED was considered to be used at baseline if started any time prior to first dose of study drug and continued to the titration period. AEDs used as rescue medication at baseline are not included.

As specified by the study protocol, none of the patients took OXC during the baseline period.

Efficacy
--------

### Seizure frequency

In the ITT population (Table[2](#tbl2){ref-type="table"}), during the 12-week maintenance period seizure frequency was significantly lower in the ESL 1,200 mg group (LS mean: 6.00) than the placebo group (LS mean: 7.88; log difference: −0.26; p = 0.004). Seizure frequency was also numerically lower in the ESL 800 mg group (LS mean: 6.54) than the placebo group (p = 0.06). In the PP population, similar statistically significant effects were observed during the 12-week maintenance period with ESL 1,200 mg (LS mean 5.78, log difference: −0.29, p = 0.001), but not ESL 800 mg (LS mean: 6.83; log difference: −0.13; p = 0.12) versus placebo (LS mean: 7.85).

###### 

Analysis of covariance of standardized seizure frequency during the 12-week maintenance period (ITT population)

  Study population                                                              Placebo (n = 220)   ESL 800 mg (n = 215)   ESL 1,200 mg (n = 205)
  ----------------------------------------------------------------------------- ------------------- ---------------------- ------------------------
  Overall ITT population                                                                                                   
   n                                                                            212                 200                    184
   LS mean (95% CI)                                                             7.88 (6.98--8.90)   6.54 (5.77--7.40)      6.00 (5.26--6.84)
   Log difference in LS mean versus placebo                                     --                  −0.18                  −0.26
   Bonferroni\'s procedure-adjusted p-value[*a*](#tf2-2){ref-type="table-fn"}   --                  0.06                   0.004
  ITT population (daily entry diaries)                                                                                     
   n                                                                            154                 137                    136
   LS mean (95% CI)                                                             7.54 (6.55--8.68)   6.32 (5.44--7.35)      5.96 (5.12--6.94)
   Log difference in LS mean versus placebo                                     --                  −0.17                  −0.22
   Dunnett\'s procedure-adjusted p-value[*b*](#tf2-3){ref-type="table-fn"}      --                  0.17                   0.05
  ITT population (event-entry diaries)                                                                                     
   N                                                                            58                  63                     48
   LS mean (95% CI)                                                             7.91 (6.43--9.72)   6.33 (5.17--7.72)      5.41 (4.28--6.81)
   Log difference in LS mean versus placebo                                     --                  −0.21                  −0.36
   p-value[*c*](#tf2-4){ref-type="table-fn"}                                    --                  0.13                   0.02

CI, confidence interval; ESL, eslicarbazepine acetate; ITT, intention to treat; LS, least squares.

Bonferroni\'s procedure was used to calculate the p-values and the 95% CIs for log differences.

Dunnett\'s procedure was used to calculate the p-values (assessed at p = 0.025 level) and 97.5% CIs for log differences.

Unadjusted p-value for pairwise comparison with placebo.

When analyzed for the titration and maintenance periods combined, seizure frequency was significantly lower for both the ESL 1,200 mg group (LS mean: 6.31; log difference: −0.31; p \< 0.001) and the ESL 800 mg group (LS mean: 6.60; log difference: −0.26; p = 0.001) than for the placebo group (LS mean: 8.68).

A separate ANCOVA demonstrated that there was no significant interaction between treatment and diary version used (p = 0.76); nevertheless the primary end point was analyzed separately in the EE and DE populations. Both diary groups showed similar trends across treatment groups (Table[2](#tbl2){ref-type="table"}). Although the influence of geographic region on treatment response was also not statistically significant (p = 0.38), seizure frequency was nevertheless analyzed separately for patients enrolled in North America (n = 229) and the rest of the world (n = 411). In the North American subgroup there was no statistically significant difference in seizure frequency between the ESL 1,200 mg group (LS mean: 6.57; log difference: −0.18; p = 0.18) or the ESL 800 mg group (LS mean: 7.63; log difference: −0.03; p = 0.79) and placebo (LS mean: 7.90). In the rest of the world subgroup, seizure frequency was significantly lower in both the ESL 1,200 mg group (LS mean: 5.59; log difference: −0.32, p = 0.003) and the ESL 800 mg group (LS mean: 5.87; log difference: −0.27; p = 0.010) than the placebo group (LS mean: 7.80).

### Responder rate

The responder rate in the ITT population during the maintenance phase was significantly higher in the ESL 1,200 mg group (42.6%; p \< 0.001) but not the ESL 800 mg group (30.5%; p = 0.07) compared with the placebo group (23.1%; Fig.[1](#fig01){ref-type="fig"}). In patients taking ESL 1,200 mg, a significantly greater response rate than placebo was observed in both DE (43.0% vs. 26.0%; p = 0.002) and EE (41.7% vs. 15.5%; p = 0.002) diary groups.

![Responder rate (proportion of patients with ≥50% reduction in seizure frequency during the maintenance period versus baseline; ITT population). CI, confidence interval; ESL, eslicarbazepine acetate. \*ESL group versus placebo.](epi0056-0244-f1){#fig01}

### Reduction in seizure frequency

Overall, the median percent reduction in seizure frequency was 21.8% in the placebo group, 29.7% in the ESL 800 mg group, and 35.6% in the ESL 1,200 mg group. The difference from placebo was significant for the 1,200 mg group (p = 0.02) but not for the ESL 800 mg group (p = 0.07). A similar pattern was observed for different seizure types: simple partial seizures were reduced by 26.5%, 36.6%, and 34.1%; complex partial seizures were reduced by 17.2%, 28.2%, and 34.1%; and partial seizures evolving to secondarily generalized seizures were reduced by 18.7%, 35.9%, and 37.0% (for placebo, ESL 800 mg, and ESL 1,200 mg, respectively). A ≥25% increase in seizure frequency occurred in 31 (14.6%), 26 (13.0%), and 24 (13.1%) patients (placebo, ESL 800 mg, and ESL 1,200 mg, respectively); differences between treatment groups were not statistically significant in the subgroup analyses.

### Seizure freedom

Seizure freedom (during the maintenance period) was achieved by 0.9% of placebo-treated patients, and 2.0% and 2.2% of ESL 800- and 1,200 mg-treated patients, respectively.

### CGI and QOLIE-31 scores

The proportions of patients with improvements on the CGI-I and the CGI efficacy scales are shown in Table[3](#tbl3){ref-type="table"}, as are the changes in CGI-S and QOLIE-31 scores between baseline and the end of the maintenance period. There were somewhat greater reductions in CGI-S scores with ESL 800 mg and ESL 1,200 mg than with placebo, although the differences were not statistically significant. Overall, 35.3% of patients taking ESL were rated either "very much improved" or "much improved" on the CGI-I scale, versus 20.7% of those taking placebo. Similarly, 44.7% of patients overall who were taking ESL had a "marked" or "moderate" improvement according to the CGI efficacy index, versus 27.8% of those on placebo. Treatment with ESL 1,200 mg and ESL 800 mg led to an increase in total QOLIE-31 scores of approximately five points between baseline and the end of the maintenance period.

###### 

CGI and QOLIE-31 scores (ITT population)

                                                                                                                   Placebo (n = 220)   ESL 800 mg (n = 215)   ESL 1,200 mg (n = 205)
  ---------------------------------------------------------------------------------------------------------------- ------------------- ---------------------- ------------------------
  CGI-S (change from baseline)[*a*](#tf3-2){ref-type="table-fn"}^,^[*b*](#tf3-3){ref-type="table-fn"}                                                         
   LS mean (95% CI)                                                                                                −0.3 (−0.4, −0.1)   −0.5 (−0.6, −0.3)      −0.4 (−0.6, −0.3)
   Unadjusted p-value                                                                                                                  0.054                  0.13
  CGI-I[*a*](#tf3-2){ref-type="table-fn"}^,^[*c*](#tf3-4){ref-type="table-fn"}                                                                                
   Very much improved, % (n)                                                                                       4.2 (9)             6.9 (14)               6.1 (12)
   Much improved, % (n)                                                                                            16.5 (35)           27.5 (56)              30.1 (59)
  CGI efficacy index (therapeutic effect)[*a*](#tf3-2){ref-type="table-fn"}^,^[*d*](#tf3-5){ref-type="table-fn"}                                              
   Marked improvement, % (n)                                                                                       4.4 (9)             9.8 (19)               10.5 (19)
   Moderate improvement, % (n)                                                                                     23.4 (48)           32.6 (63)              36.5 (66)
  QOLIE-31 total score (change from baseline)[*a*](#tf3-2){ref-type="table-fn"}                                                                               
   Mean ± SD                                                                                                       2.16 ± 25.4         5.35 ± 23.8            4.64 ± 25.7

CGI, Clinical Global Impressions; CGI-I, CGI-Improvement; CGI-S, CGI-Severity of illness; CI, confidence interval; ESL, eslicarbazepine acetate; LS, least squares; QOLIE-31, Quality of Life Epilepsy Inventory-31; SD, standard deviation.

Based on last assessment at the end of the maintenance period. Note that not all subjects had evaluable data; percentages are based on evaluable subjects.

n = 213, 205, and 198 for placebo, ESL 800 mg, and ESL 1,200 mg, respectively.

n = 212, 204, and 196 for placebo, ESL 800 mg, and ESL 1,200 mg, respectively.

n = 205, 193, and 181 for placebo, ESL 800 mg, and ESL 1,200 mg, respectively.

Safety
------

### TEAEs

The incidence of TEAEs (Table[4](#tbl4){ref-type="table"}), TEAEs considered potentially related to treatment, and TEAEs leading to discontinuation increased with ESL dose. The majority of TEAEs were of mild or moderate severity, the most common being dizziness, somnolence, nausea, headache, and diplopia (Table[4](#tbl4){ref-type="table"}). The percentage of patients who had at least one severe TEAE was 6.7% for placebo, 11.1% for ESL 800 mg, and 14.8% for ESL 1,200 mg. TEAEs classed as severe and reported in ≥2% of patients were dizziness (1.3%, 1.9%, and 3.8%) and vertigo (0%, 0.5%, and 2.9%) for placebo, ESL 800 mg, and ESL 1,200 mg, respectively. TEAEs leading to discontinuation in ≥2% of patients taking ESL (either dose) were dizziness, nausea, vomiting, ataxia, dysarthria, and somnolence (Table[4](#tbl4){ref-type="table"}). TEAEs of special interest included depression (reported in 2.7%, 2.3%, and 2.4% of the placebo, ESL 800 mg, and ESL 1,200 mg groups, respectively) and rash (reported in 1.8%, 1.4%, and 2.4% of the placebo, ESL 800 mg, and ESL 1,200 mg groups, respectively).

###### 

TEAEs affecting ≥5% of patients, TEAEs leading to discontinuation in ≥2% of patients, all serious TEAEs, and deaths (safety population)

                                             Number (%) of patients                
  ------------------------------------------ ------------------------ ------------ ------------
  Any TEAE                                   125 (55.8)               145 (67.1)   163 (77.6)
   Dizziness                                 19 (8.5)                 34 (15.7)    55 (26.2)
   Somnolence                                12 (5.4)                 16 (7.4)     36 (17.1)
   Nausea                                    11 (4.9)                 16 (7.4)     32 (15.2)
   Headache                                  17 (7.6)                 20 (9.3)     24 (11.4)
   Vomiting                                  3 (1.3)                  6 (2.8)      23 (11.0)
   Diplopia                                  4 (1.8)                  14 (6.5)     22 (10.5)
   Vertigo                                   1 (0.4)                  6 (2.8)      15 (7.1)
   Fatigue                                   6 (2.7)                  8 (3.7)      11 (5.2)
  Potentially related TEAE                   83 (37.1)                111 (51.4)   140 (66.7)
  TEAEs leading to discontinuation           18 (8)                   26 (12.0)    54 (25.7)
   Dizziness                                 1 (0.4)                  11 (5.1)     19 (9.0)
   Nausea                                    0                        3 (1.4)      13 (6.2)
   Vomiting                                  0                        0            8 (3.8)
   Ataxia                                    0                        1 (0.5)      8 (3.8)
   Dysarthria                                0                        0            5 (2.4)
   Somnolence                                2 (0.9)                  2 (0.9)      5 (2.4)
  Serious TEAEs                              7 (3.1)                  14 (6.5)     3 (1.4)
  Deaths[*a*](#tf4-2){ref-type="table-fn"}   1 (0.4)                  1 (0.5)      0

ESL, eslicarbazepine acetate; TEAE, treatment-emergent adverse event.

Data are based on the double-blind, placebo-controlled period.

### Deaths

One death occurred during the baseline period of a patient who had not received the study drug. Two deaths occurred during the double-blind period: a 29-year-old Caucasian woman randomized to placebo died of acute respiratory failure after being diagnosed with pneumonia; and a 27-year-old Caucasian man randomized to ESL 800 mg was found dead in bed with a bitten tongue (during the titration phase, while receiving 400 mg ESL). The cause of death according to the autopsy report was status epilepticus.

### Serious adverse events

There were no notable differences in the types of serious TEAEs between treatment groups, and no dose-related trends (the incidence of serious TEAEs was 3.1% for placebo, 6.5% for ESL 800 mg, and 1.4% for ESL 1,200 mg). One patient with a history of suicidal tendencies had a suicide attempt but, as she had responded to the study drug, she was allowed to continue on ESL 800 mg; no other psychiatric symptoms were reported. One serious cutaneous event (leukocytoclastic vasculitis) leading to discontinuation of treatment was reported in a patient taking ESL 800 mg.

### Clinical laboratory assessments

Overall, changes in clinical laboratory parameters (other than serum sodium) were not substantially different between the three groups. Data for reductions in serum sodium concentrations are shown in Table[5](#tbl5){ref-type="table"}. Overall, 5.1% of patients taking ESL had a reduction in serum sodium of \>10 mEq/L, compared with 0.9% of those taking placebo, whereas hyponatremia (serum sodium \<125 mEq/L) occurred in 1.5% and 0% of patients, respectively. Between baseline and week 8 of treatment (week 6 of the maintenance period), there were greater reductions in mean serum sodium with ESL 800 mg (−1.6 mEq/L) and ESL 1,200 mg (−2.2 mEq/L) than with placebo (0.1 mEq/L); the reductions tended to stabilize after approximately 2 months of treatment. Hyponatremia was reported as an adverse event (AE) leading to discontinuation in three patients taking ESL 1,200 mg (1.4%), but no patients taking placebo or ESL 800 mg. Vital signs, body weight, and electrocardiography parameters were not substantially different across visits for the placebo and ESL groups. ESL 800 and 1,200 mg had no notable effect on C-SSRS scores.

###### 

Serum sodium levels (safety population)

                                                          No. (%) of patients[*a*](#tf5-2){ref-type="table-fn"}^,^[*b*](#tf5-3){ref-type="table-fn"}                        
  ------------------------------------------------------- -------------------------------------------------------------------------------------------- --------- ---------- ----------
  Serum sodium \<125 mEq/L                                0                                                                                            1 (0.5)   5 (2.5)    6 (1.5)
  Reduction from baseline in serum sodium of \>10 mEq/L   2 (0.9)                                                                                      9 (4.3)   12 (5.9)   21 (5.1)

ESL, eslicarbazepine acetate; mEq/L, milliequivalent/liter.

Data are for patients in the safety population with at least one post-baseline sodium assessment. Note that not all subjects had evaluable data; percentages are based on evaluable subjects.

n = 220, 209, 204, and 413 for placebo, ESL 800 mg and ESL 1,200 mg, and Total ESL, respectively.

Discussion
==========

ESL was developed to enhance the yield of the pharmacologically desirable metabolite eslicarbazepine, while reducing exposure to the less pharmacologically desirable metabolites (R)-licarbazepine and OXC.

The present study confirms and extends the findings of efficacy and safety of ESL as adjunctive treatment of partial-onset seizures as reported in two prior randomized placebo-controlled trials.[@b11],[@b12] Once-daily ESL was effective as adjunctive therapy and was generally well tolerated in patients with refractory partial-onset (focal) seizures. During the 12-week maintenance period, seizure frequency was significantly reduced in the ESL 1,200 mg group compared with placebo (p = 0.004), and there was a trend toward improvement in the ESL 800 mg group compared with placebo (p = 0.06). No statistically significant interactions between ESL treatment and geographical region or ESL treatment and diary version (DE or EE) were detected. For the majority of secondary efficacy end points, including response rate and reduction in seizure frequency, there were statistically significant differences between ESL 1,200 mg and placebo, and similar trends occurred with ESL 800 mg. We noted relatively high 50% responder rates in placebo-treated patients, approximating rates reported in other studies of similar design (e.g., perampanel, 19.3%;[@b18] lacosamide, 23.0%;[@b19] and OXC, 28.1%[@b20]). This poses a challenge in interpreting the magnitude of effect of new AEDs. Nonetheless, substantially more patients taking ESL were rated at least "much improved" on the CGI-I scale, or had at least "moderate improvement" according to the CGI efficacy scale compared with placebo-treated patients. Patients taking ESL had improvements in QOLIE-31 scores of approximately five points (i.e., comparable to the minimal clinically important improvement described by Borghs et al.),[@b21] indicating that treatment with ESL led to clinically meaningful improvements in quality of life.

In this study, seizure frequency was the primary efficacy end point. Similar clinical trials[@b22],[@b23] previously used either the median percentage change in seizure frequency from baseline, or the responder rate as the primary outcome measure. These measures are susceptible to bias when the distribution of seizure frequencies is not normally distributed. In such circumstances, the log-transformed seizure frequency is a more robust measure, as discussed in an analysis by Siddiqui and Hershkowitz.[@b24]

The current safety and tolerability findings are consistent with those reported previously for ESL.[@b11],[@b12] The most commonly reported TEAEs were dizziness, somnolence, nausea, headache, vomiting, diplopia, vertigo, and fatigue. Rash was reported in 1.4% and 2.4% of patients, and hyponatremia in 0% and 1.5% of patients (taking ESL 800 and 1,200 mg, respectively). Too few cases occurred to draw conclusions regarding dose and incidence of symptomatic hyponatremia. In previous studies of OXC, rash was reported in 6% of patients[@b25] and hyponatremia in 3.8% of adult patients.[@b26] The incidence of TEAEs and TEAEs leading to discontinuations was higher in the ESL 1,200 mg group than the ESL 800 mg group. However, somewhat more patients in the 1,200 mg group than the 800 mg group were taking other concomitant AEDs with the same mode of action as ESL (sodium channel blockers, i.e., CBZ, lamotrigine). It has been reported that combining sodium channel blockers may lead to increased toxicity.[@b27]

As in previous ESL trials, these findings indicate that ESL is effective as adjunctive therapy in patients with a long history of partial seizures and poor seizure control, who are taking one or two concomitant AEDs. ESL demonstrated efficacy in patients who previously had continued to have frequent seizures, despite treatment with AEDs including CBZ, levetiracetam, lamotrigine and valproic acid. The current trial is generally consistent with previous trials[@b11],[@b12] in which once-daily ESL (800 and/or 1,200 mg) was efficacious and well-tolerated in patients with refractory partial-onset seizures. In the current trial, the ESL 800 mg dose did not reach statistical significance. It is not clear why this occurred, however, the trends toward improvements were consistent with results in previous studies. Too few patients (n = 36) in the entire ESL development program were taking three concomitant AEDs to assess efficacy as a function of number of AEDs.

One important methodologic difference between this trial and previous studies was the use of DE diaries to ensure that seizure data were recorded on every day of the trial, regardless of whether seizures had occurred. Reliability of seizure recording is a key issue in epilepsy trials,[@b28] but to date no formal comparisons of seizure diaries of different designs are available. In the present study, the interaction between the effect of treatment and diary version was not significant (p = 0.76). The results obtained with DE diaries were consistent with those obtained with EE diaries. Selection of diary type was based on time of enrollment, rather than by randomization, which represents a limitation in the method.

Conclusions
===========

In this phase III study, daily dosing with adjunctive ESL was effective in reducing seizures in patients with refractory partial-onset (focal) seizures, and was generally well tolerated. The effect of ESL 1,200 mg on seizure frequency was significantly greater than that of placebo; whereas ESL 800 mg also reduced seizure frequency, the difference versus placebo was not statistically significant. The DE and EE diary methods produced similar results with regard to seizure outcomes; this is the first clinical trial providing efficacy data in patients with partial-onset seizures who used two different diary designs. ESL is a useful addition to current AED pharmacotherapy for the treatment of refractory partial-onset (focal) seizures, on the basis of clinical activity, convenient once-daily dosing, and good tolerability.
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**Figure S1.** Patient disposition.
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**Appendix S1.** The 304 study team.
